Literature DB >> 14741215

Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.

Oliver Schon1, Assaf Friedler, Stefan Freund, Alan R Fersht.   

Abstract

We have used NMR to study the effects of peptide binding on the N-terminal p53-binding domain of human MDM2 (residues 25-109). There were changes in HSQC-chemical shifts throughout the domain on binding four different p53-derived peptide ligands that were significantly large to be indicative of global conformational changes. Large changes in chemical shift were observed in two main regions: the peptide-binding cleft that directly binds the p53 ligands; and the hinge regions connecting the beta-sheet and alpha-helical structures that form the binding cleft. These conformational changes reflect the adaptation of the cleft on binding peptide ligands that differ in length and amino acid composition. Different ligands may induce different conformational transitions in MDM2 that could be responsible for its function. The dynamic nature of MDM2 might be important in the design of anti-cancer drugs that are targeted to its p53-binding site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741215     DOI: 10.1016/j.jmb.2003.11.051

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.

Authors:  Erin G Worrall; Bartosz Wawrzynow; Liam Worrall; Malcolm Walkinshaw; Kathryn L Ball; Ted R Hupp
Journal:  J Chem Biol       Date:  2009-05-16

2.  Entropy Hotspots for the Binding of Intrinsically Disordered Ligands to a Receptor Domain.

Authors:  Jie Shi; Qingliang Shen; Jae-Hyun Cho; Wonmuk Hwang
Journal:  Biophys J       Date:  2020-04-08       Impact factor: 4.033

Review 3.  Intrinsically disordered proteins in cellular signalling and regulation.

Authors:  Peter E Wright; H Jane Dyson
Journal:  Nat Rev Mol Cell Biol       Date:  2015-01       Impact factor: 94.444

4.  Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation.

Authors:  Chul Won Lee; Josephine C Ferreon; Allan Chris M Ferreon; Munehito Arai; Peter E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-20       Impact factor: 11.205

5.  MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change.

Authors:  Hongxia Xu; Zhuo Zhang; Mao Li; Ruiwen Zhang
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

6.  Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction.

Authors:  Xiaoying Wang; Patrycja Magdziarz; Ernest Enriquez; Wang Zhao; Chris Quan; Narek Darabedian; Jamil Momand; Feimeng Zhou
Journal:  Anal Biochem       Date:  2019-02-02       Impact factor: 3.365

7.  Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics.

Authors:  Gennady M Verkhivker
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

8.  Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.

Authors:  L Michel Espinoza-Fonseca
Journal:  Theor Biol Med Model       Date:  2005-09-20       Impact factor: 2.432

9.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931

Review 10.  Targeting the p53-MDM2 interaction to treat cancer.

Authors:  C Klein; L T Vassilev
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.